📊 EXOZ Key Takeaways
Is Exozymes Inc.. (EXOZ) a Good Investment?
Exozymes is a pre-revenue biotech company with severe cash burn and no clear path to profitability. Operating losses of $7.0M on revenue of only $70.1K demonstrate the company is in early-stage development with minimal commercial traction. At current burn rates, the company's $5.1M cash position provides less than 14 months of runway.
Exozymes shows extremely weak fundamental operating performance, with negligible revenue relative to a multi-million-dollar loss base and deeply negative operating, net, and free cash flow margins. While the balance sheet is currently supported by solid liquidity, low liabilities, and no meaningful debt, the business does not yet demonstrate scalable revenue generation or a credible path to self-funded profitability.
Why Buy Exozymes Inc.. Stock? EXOZ Key Strengths
- Strong liquidity position with $5.1M cash and 4.53x current ratio
- Zero long-term debt provides financial flexibility
- Low liabilities relative to assets ($2.3M liabilities vs $7.7M assets)
- Strong near-term liquidity with $5.10M in cash and a 4.53x current ratio
- Low balance-sheet leverage with essentially no long-term debt
- Positive equity base of $5.37M provides some financial cushion
EXOZ Stock Risks: Exozymes Inc.. Investment Risks
- Extreme cash burn of $4.5M annually with only $70.1K in revenue
- Negative operating margin of -10020% indicates business model not yet viable
- Limited cash runway of approximately 14 months at current burn rates without additional funding
- No insider purchases in last 90 days suggests limited management confidence
- Operating losses increasing with diluted EPS declining 169.7% year-over-year
- Revenue remains extremely small at $70.07K versus $6.50M net loss, indicating a highly unproven commercial model
- Cash burn is severe, with negative operating cash flow of $4.53M and free cash flow of $4.62M
- Profitability metrics are deeply negative, including -10020.1% operating margin and -121.0% ROE
Key Metrics to Watch
- Revenue growth rate and path to commercialization
- Monthly cash burn rate and remaining runway
- Operating expense efficiency and progress toward profitability
- Capital raises and dilution impact on equity holders
- Clinical or product development milestones
- Quarterly revenue growth and commercialization traction
- Operating cash burn relative to cash balance
Exozymes Inc.. (EXOZ) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 4.53x current ratio provides a solid financial cushion.
EXOZ Profit Margin, ROE & Profitability Analysis
EXOZ vs Healthcare Sector: How Exozymes Inc.. Compares
How Exozymes Inc.. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Exozymes Inc.. Stock Overvalued? EXOZ Valuation Analysis 2026
Based on fundamental analysis, Exozymes Inc.. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Exozymes Inc.. Balance Sheet: EXOZ Debt, Cash & Liquidity
EXOZ Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Exozymes Inc..'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-0.89 indicates the company is currently unprofitable.
EXOZ Revenue Growth, EPS Growth & YoY Performance
EXOZ Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2024 | $70.8K | -$178.1K | $-0.08 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Exozymes Inc.. Dividends, Buybacks & Capital Allocation
EXOZ SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Exozymes Inc.. (CIK: 0002010788)
📋 Recent SEC Filings
❓ Frequently Asked Questions about EXOZ
What is the AI rating for EXOZ?
Exozymes Inc.. (EXOZ) has a Combined AI Rating of STRONG SELL from Claude (STRONG SELL) and ChatGPT (STRONG SELL) with 93% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are EXOZ's key strengths?
Claude: Strong liquidity position with $5.1M cash and 4.53x current ratio. Zero long-term debt provides financial flexibility. ChatGPT: Strong near-term liquidity with $5.10M in cash and a 4.53x current ratio. Low balance-sheet leverage with essentially no long-term debt.
What are the risks of investing in EXOZ?
Claude: Extreme cash burn of $4.5M annually with only $70.1K in revenue. Negative operating margin of -10020% indicates business model not yet viable. ChatGPT: Revenue remains extremely small at $70.07K versus $6.50M net loss, indicating a highly unproven commercial model. Cash burn is severe, with negative operating cash flow of $4.53M and free cash flow of $4.62M.
What is EXOZ's revenue and growth?
Exozymes Inc.. reported revenue of $70.1K.
Does EXOZ pay dividends?
Exozymes Inc.. does not currently pay dividends.
Where can I find EXOZ SEC filings?
Official SEC filings for Exozymes Inc.. (CIK: 0002010788) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is EXOZ's EPS?
Exozymes Inc.. has a diluted EPS of $-0.78.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is EXOZ a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Exozymes Inc.. has a STRONG SELL rating with 93% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is EXOZ stock overvalued or undervalued?
Valuation metrics for EXOZ: ROE of -121.0% (sector avg: 15%), net margin of -9,281.8% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy EXOZ stock in 2026?
Our dual AI analysis gives Exozymes Inc.. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is EXOZ's free cash flow?
Exozymes Inc..'s operating cash flow is $-4.5M, with capital expenditures of $94.9K. FCF margin is -6,598.0%.
How does EXOZ compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -9,281.8% (avg: 12%), ROE -121.0% (avg: 15%), current ratio 4.53 (avg: 2).